Observational evidence demonstrates the safety of GLP-1 receptor agonists in older individuals with type 2 diabetes, suggesting clinical phenotype-driven selection is necessary.
Current RW evidence supports GLP-1RA as a safe therapeutic option for older individuals with T2DM, without age-specific safety signals. Clinical phenotype-driven selection is essential to balance benefits and risks, particularly regarding nutritional status and frailty. Prospective, phenotype-stratified studies with body composition assessment are needed to guide optimal, individualized use in aging populations.
No takes yet. Share an insight, caveat, or question.
Marassi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: